Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 20, 2007
Last updated: February 14, 2008
Last verified: February 2008

Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency & severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists

- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

Further study details as provided by AstraZeneca:

Estimated Enrollment: 900
Study Start Date: July 2007

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with newly occured upper GI symptoms related to GERD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00567619

Research Site
Vienna, Austria
Sponsors and Collaborators
Study Chair: Not required for Study Not required for this study
  More Information Identifier: NCT00567619     History of Changes
Other Study ID Numbers: NIS-GAT-NEX-2007/1
Study First Received: September 20, 2007
Last Updated: February 14, 2008

Keywords provided by AstraZeneca:
NIS processed this record on May 23, 2017